<DOC>
	<DOCNO>NCT00089921</DOCNO>
	<brief_summary>The primary objective study determine efficacy oral SCIO-469 patient rheumatoid arthritis receive liver damaging ( hepatotoxic ) disease-modifying anti-rheumatic drug ( DMARDs ) .</brief_summary>
	<brief_title>SPRiNG : SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate</brief_title>
	<detailed_description>This 24 week randomize ( study drug assign chance ) , double blind ( neither physician patient know name assign drug ) , placebo control , parallel group study assess safety effectiveness oral SCIO-469 treating patient rheumatoid arthritis receive liver damaging ( hepatotoxic ) disease-modifying anti-rheumatic drug ( DMARDs ) . The patient participate study approximately 183 day . Safety measure include vital sign ( blood pressure , pulse rate , breathe rate ) , 12-lead electro-cardiogram , adverse event , concomitant medication , clinical laboratory evaluation ( include serum chemistry , hematology , qualitative urinalysis , liver function test ) . The patient may assign receive 30 mg capsule orally ( mouth ) one two capsule three time daily , receive 100 mg tablet orally daily , placebo ( active drug ) orally two capsule three time daily placebo tablet orally daily 24 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients active rheumatoid arthritis receive medication know hepatotoxic diseasemodifying antirheumatic drug ( DMARDs ) Patients take hydroxychloroquine ( Plaquenil ) must stable consistent dose prior enter study Patients use Enbrel , Remicade , Kineret , Humira , experimental biologic agent within past 3 month Lab test reveal elevate liver enzymes within past 6 month Medical history Tuberculosis , cancer , multiple sclerosis , neuropathy encephalopathy HIV positive Abnormal electrocardiogram Chronic acute infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>DMARDs</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>p38 kinase</keyword>
</DOC>